Description
Livmarli (maralixibat) is a medication used to treat pruritus (itching) associated with Alagille syndrome in patients aged 1 month and above. Alagille syndrome is a rare genetic disorder that affects various body systems, including the liver and the biliary tract, leading to reduced bile flow and accumulation of bile acids in various organs, including the liver. This accumulation causes severe itching (pruritus), which Livmarli aims to alleviate.
Uses:
Livmarli is used to treat pruritus (itching) associated with Alagille syndrome in patients aged 1 month and above.
Storage Conditions:
Livmarli should be stored in its original packaging between 20°C to 25°C (68°F to 77°F). The medication should be protected from light, moisture, and heat.
Mechanism of Action:
Livmarli works by inhibiting the ileal bile acid transporter (IBAT) which reduces the absorption of bile acids in the intestines, thereby regulating their levels in the liver and other organs. This mechanism helps alleviate pruritus (itching) associated with Alagille syndrome.
HOW TO USE:
Livmarli is taken orally twice daily, with or without food, and the dosage is based on the patient’s age, weight, and other factors. The dosage should be adjusted following recommendations from the prescribing healthcare provider. The medication should be taken at the same time every day to achieve the best results. Livmarli should always be taken under the supervision of a healthcare professional.
Precautions:
• Livmarli should not be used in patients with known hypersensitivity to maralixibat or any of its components.
• The medication may cause liver function abnormalities. For this reason, patients with liver disease or who are using medications that can potentially affect liver function should undergo liver function tests before starting treatment with Livmarli and monitored regularly during treatment.
• Livmarli may interact with other medications that affect bile acid metabolism, such as bile acid sequestrants or oral contraceptives. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are taking before receiving treatment with Livmarli.
Drug Interactions:
Livmarli may interact with other medications that affect bile acid metabolism, such as bile acid sequestrants or oral contraceptives. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are taking before receiving treatment with Livmarli.
Contraindications:
Livmarli should not be used in patients with known hypersensitivity to maralixibat or any of its components.
Overdose:
There is no specific information about the risk of an overdose with Livmarli. In case of an overdose, patients should seek medical attention immediately.
Adverse Reactions:
The most common adverse reactions associated with treatment with Livmarli include diarrhea, abdominal pain, nausea, and vomiting. Patients should contact their healthcare provider if they experience any unusual reactions while using Livmarli.
In conclusion, Livmarli is a medication used to treat pruritus (itching) associated with Alagille syndrome in patients aged 1 month and above. The medication inhibits the ileal bile acid transporter (IBAT), which reduces the absorption of bile acids in the intestines and helps alleviate the accumulation of bile acids that cause pruritus. Livmarli is taken orally twice daily, with or without food, and should be stored in its original packaging at room temperature. Patients should take precautions, such as undergoing liver function tests and informing their healthcare providers of all medications they are taking. Livmarli may interact with other medications, and patients with hypersensitivity to maralixibat or any of its components should not use the medication. The medication has several adverse reactions, such as diarrhea and vomiting and patients should contact their healthcare provider if they experience any unusual reactions.
Reviews
There are no reviews yet.